The Medical Letter on Drugs and Therapeutics
FROM
ISSUE 1728
ISSUE 1728
May 12, 2025
Issue 1728
- Cologuard Plus — An At-Home Stool DNA Test for Colorectal Cancer Screening
- Landiolol (Rapiblyk) for Short-Term Rate Control in Supraventricular Tachycardia
- Concizumab (Alhemo) for Hemophilia A and B with Inhibitors
- Mirikizumab (Omvoh) – An IL-23 Antagonist for Crohn's Disease
- In Brief: A Home Test for Chlamydia, Gonorrhea, and Trichomoniasis
Subscribers: Log in to read full issue. Not a subscriber? Subscribe or purchase issue.
Cologuard Plus — An At-Home Stool DNA Test for Colorectal Cancer Screening
May 12, 2025 (Issue: 1728)
The FDA has approved Cologuard Plus (Exact
Sciences), a new at-home multitarget stool DNA test,
for colorectal cancer (CRC) screening in average-risk
adults ≥45 years old. Cologuard, the first FDA-approved
multitarget stool DNA test, has been...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.